ADDF provides $248.
ADDF provides $248,000 grant to ALSP to permit its lead drug candidate towards clinical trials The Alzheimer’s Medication Discovery Base announced today that it’s providing a grant of $248,000 to American Life Science Pharmaceuticals, Inc. to allow for produce of its lead medication candidate to be utilized in preclinical toxicology screening in preparation for entering Phase I clinical trials early in 2011 Click here . ALSP is developing fresh methods to effectively treat neurodegenerative disease with an initial focus on Alzheimer’s disease . ALSP has identified a new class of medicines that prevent memory space pathology and deficit in animal models of AD. ‘Our proprietary lead compound, AB-007, provides previously been evaluated for a different indication in individual clinical trials and been shown to be safe and well tolerated,’ said company CEO, Michael D.
The research, published in the Journal of Adolescent Health, discovers that both pediatric and family members medicine providers who care for children are employing screening assessments for type 2 diabetes that may bring about missed diagnoses for kids, says lead author Joyce Lee, M.D., M.P.H., associate professor in U-M's Departments of Pediatrics and Communicable Diseases and Environmental Wellness Sciences. Related StoriesStudy finds high prevalence of dehydration in the elderly living in UK care homesDiabetes prevention begins in the wombMayo Clinic investigators discover novel mechanism linked to diabetes risk In 2010 2010, the ADA suggested that physicians make use of Hemoglobin A1c screening exams, rather than glucose checks for identifying kids and adults with pre-diabetes and diabetes.